Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2001
04/26/2001WO2000071153A3 Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors
04/26/2001WO2000069415A3 Melt granulation
04/26/2001WO2000061612A3 Compounds and methods for therapy and diagnosis of lung cancer
04/26/2001WO2000061536A3 Synthesis and pharmaceuticals of novel 9-substituted-1,5-dichloroanthracene analogs
04/26/2001WO2000061151A3 Oligodeoxynucleotide and its use to induce an immune response
04/26/2001WO2000059447A3 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
04/26/2001WO2000058328A3 Avermectin derivatives
04/26/2001WO2000057869A3 Viral treatment
04/26/2001WO2000056889A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same
04/26/2001WO2000056293A3 Medicaments containing doxazosin-mesylate of crystalline modification d
04/26/2001WO2000055139A3 Heterocyclic urea and related compounds useful as anti-inflammatory agents
04/26/2001WO2000055125A3 N-cyanomethyl amides as protease inhibitors
04/26/2001WO2000051590A3 Neuropharmacological treatment of sleep-related breathing disorders
04/26/2001WO2000048445A3 Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
04/26/2001WO2000047163A3 Use of hyaluronic acid or fragments thereof for regulating hematopoietic differentiation
04/26/2001WO2000044357A3 Agent for preventing in-stent restenoses and post-operative inflammations
04/26/2001WO2000008020A8 Tricyclic carboxamides
04/26/2001WO1997035591B1 Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
04/26/2001US20010000521 Biological activity inhibiting topoisomerase I and/or topoisomerase II; antitumor agents, viricides
04/26/2001US20010000513 Treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation
04/26/2001US20010000511 Treatment of skin disorders, inflammation, nerve system disorders, cancer
04/26/2001US20010000474 Composition for inhibiting increase of blood sugar level or lowering blood sugar level
04/26/2001US20010000472 Includes Milk thistle (silybum marianum) constituents
04/26/2001US20010000471 Active medicament such as dimenhydrinate, an inner oil substance coating of given melting point, such as soybean oil, and outer coating layer of a polymeric substance such as ethyl cellulose; free of bad tastes
04/26/2001DE19950898A1 New heteroaryl substituted fluoroalkyl-benzoylguanidine derivatives useful for treatment of e.g. ischemias, cardiac infarction, angina, shock, atherosclerosis, cancer and metabolic disorders
04/26/2001DE19950647A1 Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS
04/26/2001DE19950428A1 Organic disulfides as reduction modulators for organic nitrates, useful e.g. for controlling formation of pharmaceutically active metabolites from pentaerythritol tetranitrate
04/26/2001DE19950066A1 Transdermal therapeutic system based on polyacrylate matrix carrier comprises tulobuterol hydrochloride
04/26/2001DE19949252A1 Superfizielles therapeutisches System zur topischen Applikation von Acetylsalicylsäure zur Behandlung von Akne-Erkrankungen Superficial therapeutic system for the topical application of acetylsalicylic acid for the treatment of acne diseases
04/26/2001DE19938825A1 Wirkstoffkombination mit Clonidin Drug combination with clonidine
04/26/2001DE19911555A1 Treatment of allergic conditions comprises administration of fludrocortisone
04/26/2001DE10032444A1 Enteral feeding solutions contain an alkyl paraben to inhibit growth of micro-organisms in the enteral tube
04/26/2001CA2389317A1 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
04/26/2001CA2388859A1 Inhibitors of neuraminidases
04/26/2001CA2388530A1 Therapeutic mixture of hmg-coa reductase inhibitors
04/26/2001CA2388503A1 Novel bicyclic cannabinoid agonists for the cannabinoid receptor
04/26/2001CA2388450A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas
04/26/2001CA2388427A1 Methods for improving secondary metabolite production in fungi
04/26/2001CA2388421A1 Human cub-domain-containing protein and gene encoding the same
04/26/2001CA2388166A1 Microcapsules for stabilizing cosmetic, pharmaceutical or food products
04/26/2001CA2387974A1 N-substituted 3-amino-2,2-di-c-alkyl-1,4-butyrolactones and 1,4-thiobutyrolactones for use as promoter of .gamma.-aminobutyric acid activity and for treating nervous disorders andpreparation method
04/26/2001CA2387972A1 N-substituted 1-(lactone) isoquinolones for treating nervous disorders
04/26/2001CA2387928A1 Genes associated with obesity and methods for using the same
04/26/2001CA2387925A1 Magnetic targeted carrier composed of iron and porous materials for the targeted delivery of biologically active agents
04/26/2001CA2387896A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors
04/26/2001CA2387892A1 Pyrazole derivatives as cannabinoid receptor antagonists
04/26/2001CA2387886A1 Bicyclic vasopressin agonists
04/26/2001CA2387864A1 Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
04/26/2001CA2387846A1 Retro-anandamides, high affinity and stability cannabinoid receptor ligands
04/26/2001CA2387840A1 Tyrosine kinase inhibitors
04/26/2001CA2387819A1 Sustained-release formulations for treating cns-mediated disorders
04/26/2001CA2387810A1 Novel human proteins and polynucleotides encoding the same
04/26/2001CA2387786A1 Treatment of eosinophil associated pathologies by modulating pkc-.delta. activity
04/26/2001CA2387757A1 Cobalamin conjugates useful as imaging agents and as antitumor agents
04/26/2001CA2387593A1 Enzyme inhibitors
04/26/2001CA2387558A1 Polyanhydrides with biologically active degradation products
04/26/2001CA2387348A1 Antimicrobial compositions comprising a benzoic acid analog and a metal salt
04/26/2001CA2387164A1 Anti-ischemic compounds
04/26/2001CA2387138A1 Cannabimimetic indole derivatives
04/26/2001CA2387034A1 4,5-disubstituted-2-aminopyrimidines
04/26/2001CA2386990A1 Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
04/26/2001CA2386942A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
04/26/2001CA2386910A1 New oxabispidine compounds useful in the treatment of cardiac arrhythmias
04/26/2001CA2386626A1 Targeted vectors
04/26/2001CA2386422A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
04/26/2001CA2386401A1 Preparation of cellular components that are substantially free of chromosomal dna
04/26/2001CA2386155A1 Method for producing liposome preparation
04/26/2001CA2386149A1 Allosteric sites on muscarinic receptors
04/26/2001CA2386143A1 Liposome formulation of 6,9-bis-[(2-aminoethyl)-amino]benzo[g]isoquinoline-5,10-dione dimaleate
04/26/2001CA2386049A1 Bicyclic and tricyclic amines as modulators of chemokine receptor activity
04/26/2001CA2385958A1 Inhibitors of proteasomal activity for stimulating bone and hair growth
04/26/2001CA2385472A1 Isoxazolecarboxamide derivatives
04/26/2001CA2384789A1 Synthesis and methods of use of 9-substituted guanine derivatives
04/26/2001CA2384573A1 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
04/26/2001CA2384537A1 Modulation of angiogenesis
04/26/2001CA2384240A1 Benzylcycloalkyl amines as modulators of chemokine receptor activity
04/26/2001CA2382985A1 Antimicrobial compositions comprising pyroglutamic acid and optionally metal salts
04/26/2001CA2382978A1 Powder pharmaceutical formulations
04/26/2001CA2382877A1 Aminoalkylenephosphonates for treatment of bone disorders
04/26/2001CA2382864A1 Dialysis solution including polyglycol osmotic agent
04/26/2001CA2356177A1 Aqueous pharmaceutical compositions
04/25/2001WO2000012044A2 Method for the preparation of citalopram
04/25/2001EP1094109A2 Human G protein-coupled receptor, PFI-010
04/25/2001EP1094076A1 Human G-protein coupled receptor
04/25/2001EP1094066A2 Condensed heterocyclic glutamic acid derivatives as antiproliferative agents
04/25/2001EP1094064A1 5-arylindolederivatives and their use as serotonin(5-ht1)agonists
04/25/2001EP1094063A1 9-(Piperazinylalkyl)carbazoles as Bax-modulators
04/25/2001EP1094057A1 Radical scavenger
04/25/2001EP1093819A2 Compounds and compositions for delivering active agents
04/25/2001EP1093817A1 Composition containing compounds with adrenergic activity and vegetable extracts of crataegus and gingko biloba for the treatment of overweight and obesity
04/25/2001EP1093816A2 Use of ST1435 in hormonal therapy by transdermal application
04/25/2001EP1093815A1 Oral 2-methyl-thieno-benzodiazepine formulation
04/25/2001EP1093814A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
04/25/2001EP1093813A2 Process for preparing polymer coated tablet comprising amoxycillin and clavunalate, coated with an aqueous polymeric filmcoating
04/25/2001EP1093812A2 Amoxycillin and clavulanate containing pharmaceutical formulation
04/25/2001EP1093811A1 Anti-tumor compositions containing taxan derivatives
04/25/2001EP1093810A1 Fast-dissolving tablet comprising brotizolam
04/25/2001EP1093468A1 Polymers for delivering nitric oxide in vivo
04/25/2001EP1093457A1 Cytokine receptor common gamma chain like
04/25/2001EP1093456A2 Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents